PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
Targeted multiparametric magnetic resonance imaging/ultrasound fusion biopsy for quantitative Gleason 4 rrading prediction in radical prostatectomy specimens: Implications for active surveillance candidate selection
Detection of clinically significant prostate cancer using targeted biopsy with four cores versus target saturation biopsy with nine cores in transperineal prostate fusion biopsy: A prospective randomized trial
The oncological characteristics of non-prostate-specific membrane antigen (PSMA)-expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography
The detection of prostate cancer with magnetic resonance imaging-targeted prostate biopsies is superior with the transperineal vs the transrectal approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group multi-institutional study
Effect of Peritoneal Fixation (PerFix) on lymphocele formation in robot-assisted radical prostatectomy with pelvic lymphadenectomy: Results of a randomized prospective trial
Prostate cancer incidence in men with Prostate-Specific Antigen (PSA) below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)